hn.today

Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades'

theguardian.com20 points0 comments
Screenshot of Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades'

Daraxonrasib, an oral KRAS-inhibitor drug, has shown unusually strong results in a trial involving 61 people recently diagnosed with advanced pancreatic cancer that had spread to other organs. The treatment targets mutations that drive tumour growth and shuts down their activity. During an average follow-up of 18 months, tumours stopped growing in 90% of participants, while just over 60% saw tumours shrink or disappear. In about 8% - roughly one patient in 12 - scans could no longer detect the cancer. A year after starting treatment, 76.6% of participants were alive, compared with the usual 40-45% survival rate for patients receiving chemotherapy alone.

The findings offer hope against a cancer with exceptionally poor outcomes: half of patients die within three months of diagnosis, and only about 3% survive five years when it has spread. Researchers describe the results as a major advance, noting both the depth of tumour responses and the apparent duration of disease control. But the drug cannot yet be called a cure: the trial was small, researchers do not know how long the benefits will last, and longer studies are needed to establish whether any patients achieve lasting remission. Further trials must also assess whether it can be made available through the NHS. Because KRAS mutations occur in many other cancers, the approach may have wider potential, though that possibility also requires testing.

Read on theguardian.com0 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Science

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.